×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HROW – harrow health, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HROW
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/4
06:44 am
hrow
Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/3
05:00 am
hrow
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
Medium
Report
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
2/2
07:00 am
hrow
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Medium
Report
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
1/22
06:23 pm
hrow
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]
Medium
Report
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]
1/19
06:15 am
hrow
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]
Low
Report
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]
12/3
10:37 am
hrow
How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]
Medium
Report
How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]
12/1
08:02 am
hrow
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]
Medium
Report
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]
11/24
07:00 am
hrow
Harrow to Present at Two Investor Conferences in December
Neutral
Report
Harrow to Present at Two Investor Conferences in December
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/2
08:22 am
hrow
Form 4 HARROW, INC. For: Jan 30 Filed by: Sullivan Patrick William
Low
Report
Form 4 HARROW, INC. For: Jan 30 Filed by: Sullivan Patrick William
2/2
08:21 am
hrow
Form 3 HARROW, INC. For: Jan 30 Filed by: Sullivan Patrick William
Low
Report
Form 3 HARROW, INC. For: Jan 30 Filed by: Sullivan Patrick William
2/2
07:31 am
hrow
Form 8-K HARROW, INC. For: Jan 30
Medium
Report
Form 8-K HARROW, INC. For: Jan 30
1/8
04:06 pm
hrow
Form 4 HARROW, INC. For: Jan 06 Filed by: Opaleye Management Inc.
Medium
Report
Form 4 HARROW, INC. For: Jan 06 Filed by: Opaleye Management Inc.
12/16
08:50 pm
hrow
Form 4 HARROW, INC. For: Dec 12 Filed by: BOLL ANDREW R.
Low
Report
Form 4 HARROW, INC. For: Dec 12 Filed by: BOLL ANDREW R.
12/16
08:48 pm
hrow
Form 4 HARROW, INC. For: Dec 12 Filed by: BAUM MARK L
Low
Report
Form 4 HARROW, INC. For: Dec 12 Filed by: BAUM MARK L
11/18
08:01 am
hrow
Form 8-K HARROW, INC. For: Nov 17
Low
Report
Form 8-K HARROW, INC. For: Nov 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
Q3/2019 9/30/2019 EPS -0.450 ZacksConsensus -0.020 ActVsEst (0.430) - Miss
23.5%
3/13 Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders 17.2%
3/24 ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services 9.7%
8/15 SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC 8.8%
5/9 Harrow Health Announces First Quarter 2019 Financial Results 8.2%
5/15 Harrow Health (NASDAQ: HROW) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.9%
9/5 Form 8-K HARROW HEALTH, INC. For: Sep 05 7.1%
5/12 Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/25 Harrow Health Adds Two Senior Executives to its Nashville Team 5.2%
3/3 ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA) 4.1%
3/13 Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders 17.2%
3/24 ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services 9.7%
8/15 SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC 8.8%
5/9 Harrow Health Announces First Quarter 2019 Financial Results 8.2%
5/15 Harrow Health (NASDAQ: HROW) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.9%
9/5 Form 8-K HARROW HEALTH, INC. For: Sep 05 7.1%
5/12 Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/25 Harrow Health Adds Two Senior Executives to its Nashville Team 5.2%
3/3 ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA) 4.1%
TOP News Decliners
8/14
Form 4 HARROW HEALTH, INC. For: Aug 12 Filed by: Kammer Robert J
-24.8%
3/16 Harrow Health (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $12.75 to $12.00. They now have a "buy" rating on the stock. -24.3%
3/12 ImprimisRx® Announces Supply Agreement with EyeCare Services Partners -15.0%
5/17 Form 8-K HARROW HEALTH, INC. For: May 16 -9.3%
6/28 Form 4 HARROW HEALTH, INC. For: Jun 26 Filed by: AUSTIN STEPHEN G -8.6%
8/30 Form 8-K HARROW HEALTH, INC. For: Aug 27 -7.5%
12/11 Form 8-K HARROW HEALTH, INC. For: Dec 11 -5.7%
12/4 Harrow Health (NASDAQ: HROW) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -5.2%
4/24 Form DEF 14A HARROW HEALTH, INC. For: Apr 24 -4.8%
3/9 ImprimisRx® Announces Supply Agreement with iOR Partners -4.7%
3/16 Harrow Health (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $12.75 to $12.00. They now have a "buy" rating on the stock. -24.3%
3/12 ImprimisRx® Announces Supply Agreement with EyeCare Services Partners -15.0%
5/17 Form 8-K HARROW HEALTH, INC. For: May 16 -9.3%
6/28 Form 4 HARROW HEALTH, INC. For: Jun 26 Filed by: AUSTIN STEPHEN G -8.6%
8/30 Form 8-K HARROW HEALTH, INC. For: Aug 27 -7.5%
12/11 Form 8-K HARROW HEALTH, INC. For: Dec 11 -5.7%
12/4 Harrow Health (NASDAQ: HROW) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -5.2%
4/24 Form DEF 14A HARROW HEALTH, INC. For: Apr 24 -4.8%
3/9 ImprimisRx® Announces Supply Agreement with iOR Partners -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: